Tribal Therapeutics

Tribal Therapeutics is a Cambridge-based biotechnology company focused on discovering and developing novel therapeutics by leveraging the unique genetic insights of founder populations. Founded by former Merck R&D chief Peter Kim and backed by Atlas Venture, the company utilizes a platform that identifies rare genetic variants with large phenotypic effects to uncover high-conviction drug targets. Tribal's approach aims to translate these genetic discoveries into precision medicines for a range of indications, including metabolic and cardiovascular diseases. The company operates in the pre-clinical stage, focusing on target validation and early-stage drug discovery.